Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
KRAS-targeted Drugs R&D Service

KRAS-targeted Drugs R&D Service

Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

KRAS-targeted Drugs R&D Service

RAS is one of the most frequently mutated oncogenes in human cancer. KRAS is the isoform most frequently mutated, which constitutes about 85% of RAS mutations. As the most frequently mutated RAS isoform, KRAS is intensively studied in the past years.

In the formulation of KRAS integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon provides KRAS-targeted drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services.

Download
KRAS GTPase cycle.webp

Targeting the untargetable KRAS[1]

Introduction of KRAS
Structure of KRAS
Signal Pathway of KRAS Signaling
Crystallization Studies of KRAS Protein
In Vitro Studies of KRAS-targeted Drugs
Pharmacology Evaluation of KRAS-targeted Drugs
Pharmacokinetic (PK) Studies of KRAS-targeted Drugs
Medicilon Assisted Projects
Learn more about "KRAS-targeted Drugs R&D Service"
Relevant laboratories
prev page next page
  • Pharmacokinetics refrigerator
  • Immunoassay platform
  • RAD SOURCE Small Animal X-ray irradiator
  • Details of IVIS SPECTRUM 3D imager for small animals
  • BD FACSymphoy A3
Return